Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
Surface Metals Inc. Sells Remaining Interest in Manitoba Lithium Project to Earn-in Partner Snow Lake Energy
Nine Mile Metals Announces Completion of DDH WD-25-02B and Continues to Confirm Zones of Copper Rich VMS with 66 Meters of Mineralization at the Wedge Project
